1962 Phillips Exeter Academy
1966 Yale University, New Haven, CT B.S.
1970 University of Virginia School of Medicine, Charlottesville, VA M.D.
1974-1975 Research Associate and Clinical Instructor, Department of Medicine, University of Vermont, Burlington, Vermont
1975-1979 Assistant Professor, Department of Medicine, University of Vermont, Burlington, Vermont
1979-1983 Associate Professor, Department of Medicine, University of Vermont, Burlington, Vermont
1979-1980 Acting Director, Vermont Pulmonary SCOR Program
1979-2000 Director, Pulmonary Disease & Critical Care Medicine Unit, Department of Medicine, University of Vermont, Burlington, Vermont
1983-present Professor, Department of Medicine, University of Vermont, Burlington, Vermont
1989- 1994 German-American Cooperation Program for Lung Research:Research collaboration and visitor exchange program with Institut fur Immunology, Philipps Universitat, Marburg, Germany
1993-1998 "Macrophage Cytokines (IL-1 & TNF) in Silicosis" National Heart, Lung & Blood Institute, R01-HL47069
1992-1994 Studies of a Leukotriene Receptor Antagonist, ICI-204,219 in Human Subjects with Asthma. ICI Pharmaceuticals, Inc.
1994-1995 Studies of an Inhaled Corticosteroid, Fluticasone, in Human Subjects with Asthma. Glaxo Pharmaceuticals
1994-1995 "Double-Blind, Parallel Group Evaluation of Salmeterol versus Placebo in the Treatment of Nocturnal Asthma." Glaxo Pharmaceuticals
1994-1996 "A Multinational Multicenter, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized Recombinant Human DNase I in Hospitalized Patients with Chronic Obstructive Pulmonary Disease Experiencing a Pulmonary Exacerbation." Genentech Inc.
1995-1996 "A Randomized, Double-Blind, Parallel-Group, Comparative Trial of Inhaled Fluticasone Proprionate via Multi-Dose Powder Inhaler 250 mcg bid, 500 mcg qd, and Placebo in Adolescent and Adult Subjects with Mild to Moderate Asthma." Glaxo Pharmaceuticals
1998-1999 "A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-Controlled, Dose-ranging Trial to Assess the Efficacy and Safety of Nkp 608 Microemulsion Capsules in Adult Patients with Chronic Bronchitis." Novartis Pharmaceuticals Corp.
1998-1999 "Long-term Safety of Mometasone Furoate Hfa-227 Metered Dose Inhaler and Beclomethasone Dipropionate (Vanceril) in the Treatment of Asthma Subjects Previously Maintained on Inhaled Corticosteroids (Study C97-222)." Schering-Plough Research Institute
1998-2000 "Efficacy of Avonex (hr-Interferon-$)in the Treatment of Idiopathic Pulmonary Fibrosis." Biogen, Inc.Gerald S. Davis, M.D. (Principal Investigator for site)
1999-2004 American Lung Association Asthma Clinical Research Center Program Charles H. Irvin, Ph.D. (Principal Investigator)Gerald S. Davis, M.D. (Co-Investigator)
2000-2004 "Mechanisms of Pulmonary Fibrosis Caused by Silica". National Heart, Lung & Blood Institute, R01-HL62323 Gerald S. Davis, M.D. (Principal Investigator)
2000-2003 "A Randomized, Double-Blind, Placebo – Controlled Phase III Study of the Safety and Efficacy of Subcutaneous Interferon gamma-1b (IFN( -1b) in Patients with Idiopathic Pulmonary Fibrosis." InterMune Pharmaceuticals
2001-2003 "Does the immediate FEV1.0 response to montelukast (Singulair ®)predict the long-term clinical response in patients with mild-to-moderate persistent asthma: A double-blind placebo-controlled cross-over trial" Merck & Co, Inc. Medical School Research Grant, Gerald S. Davis, M.D. (Principal Investigator)
2002-2003 “Molecular Markers of Idiopathic Pulmonary Fibrosis” Biogen, Inc (Laboratory Research Award)Gerald S. Davis, M.D. (Principal Investigator)
1966 Yale University Senior Honors Research Program
1968 University of Virginia School of Medicine Research Prize
1970 Josiah Macy Foundation History of Medicine Prize, University of Virginia
1974-1978 Edward Livingston Trudeau Fellow of the American Lung Association (Career Development Award)
Davis GS. Current therapy of idiopathic pulmonary fibrosis, in "Current Therapy in Allergy, Immunology, and Rheumatology", Lichtenstein LM, Busse WW, Geha RS (eds). Mosby, Philadelphia, PA, In press 2003.
Singh N, Davis GS. Occupational and Environmental Lung Disease. Current Opinion in Pulmonary Medicine 2002;8:117-125.Davis GS, Holmes CE, Pfeiffer LM, Hemenway DR. Lymphocytes, lymphokines, and silicosis. J Environ Pathol Toxicol Oncol 2001;20 (suppl 1):53-65.
Davis GS. Silica, in "Occupational Disorders of the Lungs", Hendrick DJ, Beckett WS, Burge PS, Churg A (eds), W.B. Saunders Co. / Harcourt Brace, London, UK, 2001.Antonini JM, Hemenway DR, Davis GS. Quantitative image analysis of lung connective tissue in murine silicosis. Exper Lung Res 2000;26:71-88.